

#6
mff
9/22/01U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

CHANGE OF CORRESPONDENCE ADDRESS

Docket Number:

Application Number
09/606,629Filing Date
June 29, 2000

Examiner

Art Unit
1615

Invention Title

CONTROLLED ABSORPTION DILTIAZEM
PHARMACEUTICAL FORMULATION

Inventor(s)

HEINICKE et al

Address to:
Assistant Commissioner for Patents
Washington D.C. 20231It is respectfully requested that future correspondence in this application be sent to the following
attorney of record:

E. Brendan Magrab ✓
FAULDING INC.
200 Elmora Avenue
Elizabeth, New Jersey 07207
(908) 659-2575 (phone)
(908) 659-2410 (facsimile)

FH FAULDING & CO. LIMITED

Date: 1/29/01

By:

Dianoosh Salehi
Dianoosh Salehi, Esq.
Reg. No. 46,352

344525

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

CERTIFICATE UNDER 37 C.F.R. 3.73(b)

Docket Number

Application Number
09/606,629

Filing Date
June 29, 2000

Examiner
To be assigned

Art Unit
1615

Invention Title
**CONTROLLED ABSORPTION DILITAZEM
PHARMACEUTICAL FORMULATION**

Inventor(s)
Grant W. Heinicke et al.

Address to:
Assistant Commissioner for Patents
Washington D.C. 20231

FH Faulding & Co. Limited, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application identified above which was recorded in the Patent and Trademark Office under Reel 9262, Frame 0670.

☒ Copies of assignment or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date : 8/11/2000

Name : E. Brendan Magrab

Title : Attorney of Record (Reg. No. 36,205)

Signature : E. B. Magrab

Received by twn 8/22/01

Facsimile Transmission

To Helen Guyen
Fax No 703 - 308 7924
From E. Brendan Magrab, Esq.

Subject Record of "Change of Address" filed in PTO on 06/29/2000

Ref Application No. 09/606,629

Date 08/22/2001



Faulding Pharmaceuticals
A division of F H Faulding & Co Limited

200 Elmora Avenue
Elizabeth
New Jersey 07207
United States

Telephone
+1 908 659 2409
Facsimile
+1 908 659 2410

www.faulding.com
jacki.cheslow@us.faulding.com

Total Pages 3

Please phone if this message is incomplete or illegible.

The information contained in this facsimile message is intended only for the personal and confidential use of the recipient(s) named above. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

Attached records showing the correct mailing address